Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes
- Sponsor
- Endogenex, Inc.
- Study ID
- NCT04725890
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- The DyaMX Device — DEVICEThe DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
Study Details
This is an open-label study to assess the safety and feasibility of the DyaMX device for endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately controlled on glucose-lowering medications.
Key Dates
- Start date
- Apr 20, 2021
- Status verified
- Mar 2025
- Primary completion
- Mar 1, 2024
- Completion
- Dec 22, 2024
Study Design
- Enrollment
- 65 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: InterventionAll eligible participants will receive the DyaMX procedure.
Primary Outcome Measure
Number of Participants With Device- or Procedure-related Serious Adverse Events (SAE) [ Time Frame: At 12 weeks post procedure ]
Related Studies
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes PatientsPHASE1/PHASE2 · Not Yet Recruiting · ARKAY Therapeutics · Albany, New York
- The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older AdultsRecruiting · AdventHealth Translational Research Institute · Orlando, Florida
- Sleep and Glycemic Control in Type 2 Diabetes AdolescentsRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Brown Adipose Tissue Activation by Spinal Cord StimulationRecruiting · Oregon Health and Science University · Portland, Oregon